Estée Lauder has taken a minority stake in 111SKIN, a luxury clinical skin care brand founded by a plastic surgeon, a strategic bet on the fast-growing intersection of medical expertise and prestige beauty. The Estée Lauder Companies has announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Financial terms of the deal were not disclosed.
111SKIN distributes through luxury retail, e-commerce, and high-end spa channels, with partners including Harrods, Bluemercury, Nordstrom, Mandarin Oriental, and Aman. The brand’s direct-to-consumer business represents approximately 20% of sales, reflecting strong digital engagement with prestige consumers. North America accounts for approximately 40% of 2025 sales, with an established presence across China, the United Kingdom, Europe, and Asia Pacific.
“We are thrilled to be partnering with The Estée Lauder Companies and to unlock an exciting new chapter for 111SKIN,” Dr. Yannis and Eva Alexandrides, co-founders of 111SKIN, said. CEO Vanessa Goddevrind added: “We look forward to building on our momentum and driving future growth together.” Dr. Alexandrides will remain actively involved in the brand and continue to lead 111SKIN alongside its management team.
Why Estée Lauder Is Investing
“Skin care is entering a new phase, shaped by the convergence of procedures, longevity and beauty, as consumers increasingly seek products that deliver visible, treatment-inspired results,” Estée Lauder Companies President and CEO Stéphane de La Faverie said. “111SKIN exemplifies this shift, translating Dr. Alexandrides’ more than 35 years of surgical and aesthetic treatment experience into high-performance luxury skin care inspired by in-clinic treatments.” The investment aligns with The Estée Lauder Companies’ broader “Beauty Reimagined” strategy, which focuses on science-driven innovation and high-performance skin care.
